People
Less than a year after taking over the reins, Biotechnology Innovation Organization Chief Executive Officer Michelle McMurry-Heath is reorganizing the organization’s leadership structure.
Rochelle Walensky, who most recently served as chief of the division of infectious diseases at Massachusetts General Hospital, will become the new head of the U.S. Centers for Disease Control and Prevention under the administration of Joe Biden.
Precision medicine developer Kura Oncology is positioned to make a meaningful difference in the treatment of cancer in the next few years with its two, wholly-owned, small molecule compounds.
Kite Pharma has tapped immunotherapy expert Francesco Marincola, a former National Institutes of Health investigator, to helm the company’s cell therapy research.
Nadim Ahmed, president of hematology at BMS, is leaving the company to, according to “pursue other opportunities.”
Despite a storied career in drug design that has spanned multiple decades, James Woody believes there is still a significant amount of work left to be accomplished with the development of tumor necrosis factor inhibitor biologics.
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers and Shakers.
Billionaire entrepreneur Mark Cuban, best known as the owner of the Dallas Mavericks and an investor on the ABC business reality series “Shark Tank,” is diving into generic drugs with a new startup, dubbed Mark Cuban Cost Plus Drug Company.
Janet Woodcock, the longtime director of the Center for Drug Evaluation and Research (CDER) at the U.S. Food and Drug Administration is set to take over the top spot of the regulatory agency on an interim basis following the presidential inauguration of Joe Biden.
Like many biopharma companies, the global COVID-19 pandemic has caused delays while also offering opportunities for NeuroRx.
PRESS RELEASES